Pfizer, Inc.

Pfizer Inc. is a global pharmaceutical company headquartered in New York, focused on the discovery, development, and manufacturing of medicines and vaccines. Its portfolio spans therapeutic areas including oncology, immunology, cardiology, and rare diseases. The company is known for its COVID-19 vaccine (Comirnaty) and oral antiviral (Paxlovid), which have significantly boosted revenues in recent years.

Pfizer generates revenue primarily through the sale of patented prescription drugs and vaccines. Key revenue drivers include its COVID-19 products, the blood thinner Eliquis (co-marketed with BMS), the pneumococcal vaccine Prevnar, and the breast cancer drug Ibrance. The company also earns royalties and licensing fees from partnerships. Revenue is diversified across therapeutic areas, though COVID-19 products have recently accounted for a substantial share.

Pfizer operates in the highly competitive drug manufacturing industry, competing with other large pharma firms like Johnson & Johnson, Merck, and AbbVie. Its competitive advantages include a strong R&D pipeline, a broad product portfolio, and a global sales infrastructure. The company has a market cap of $144.54B and a P/E of 19.47, reflecting moderate valuation. Its EV/EBITDA of 7.84 suggests reasonable earnings efficiency relative to enterprise value.

Pfizer’s customers include healthcare providers, hospitals, governments, and patients. Its products are sold in over 125 countries, with the United States being the largest market. The company has a strong presence in Europe and emerging markets. Its dividend yield of 3.98% appeals to income-focused investors, while its FCF yield of 6.42% indicates solid cash generation.

An auto-generated descriptive profile based on company data, for informational purposes only.